House Committee Seeks Answers From FDA About Anticoagulant Adverse Events

(September 15, 2015, 2:19 PM EDT) -- WASHINGTON, D.C. — Two members of the House Energy and Commerce Committee on Sept. 2 asked the Food and Drug Administration what steps, if any, the agency is taking to address safety and medical errors related to the anticoagulants Coumadin and warfarin.

(Coumadin/warfarin letter available. Document #28-150917-011X.)

The letter from Committee Chair Fred Upton, R., Mich., and ranking member Frank Pallone Jr., D., N.J., was prompted by the July joint publication of an article in the Washington Post and on the website ProPublica reporting that from...
To view the full article, register now.